Is CorMedix, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for CorMedix, Inc. moved from attractive to very attractive. The company appears to be undervalued, as indicated by its PEG ratio of 0.42, which suggests strong growth potential relative to its price, and a P/E ratio of 55, which, while high, is offset by the company's robust ROCE of 38.54%. In comparison, Xeris Biopharma Holdings, Inc. has a P/E ratio of -38.70, highlighting CorMedix's relative strength in the sector.
Despite recent stock performance showing a decline of 5.13% over the past week and 8.45% over the past month, CorMedix has outperformed the S&P 500 year-to-date with a return of 25.68% compared to the index's 13.30%. This performance, combined with its strong valuation metrics, supports the conclusion that CorMedix, Inc. is undervalued in the current market.